NDAORALTABLET, FOR SUSPENSIONPriority Review
Approved
Mar 2022
Lifecycle
Peak
Competitive Pressure
8/100
Mechanism of Action
Nucleoside Reverse Transcriptase Inhibitors
Pharmacologic Class:
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Loss of Exclusivity
LOE Date
Jun 8, 2030
51 months away
Patent Expiry
Jun 8, 2030
Exclusivity Expiry
Dec 15, 2026
Patent Records (4)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 8129385 | Oct 5, 2027 | SubstanceProduct | — |
| 8129385*PED | Apr 5, 2028 | — | |
| 9242986 | Dec 8, 2029 | SubstanceProduct | — |
| 9242986*PED | Jun 8, 2030 | — |